Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Ionis Core | | | | | 641.9 | 525.2 | | 286.4 |
| Akcea Therapeutics | | | | | 64.9 | 43.4 | | |
| Total revenues | 587.4 | 810.5 | 729.3 | 1,122.6 | 599.7 | 514.2 | 372.8 | 283.7 |
| Revenue growth [+] | -27.5% | 11.1% | -35.0% | 87.2% | 16.6% | 37.9% | 31.4% | 32.5% |
| Ionis Core | | | | | 22.2% | | | 33.7% |
| Akcea Therapeutics | | | | | 49.5% | | | |
| Cost of goods sold | 14.1 | 10.8 | 11.9 | 4.4 | 1.8 | 374.6 | 0.0 | 0.0 |
| Gross profit | 573.3 | 799.6 | 717.3 | 1,118.2 | 597.9 | 139.5 | 372.8 | 283.7 |
| Gross margin | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% | 27.1% | 100.0% | 100.0% |
| Selling, general and administrative | 150.3 | 186.3 | 354.3 | 286.6 | 244.6 | 108.5 | 48.6 | 37.2 |
| Research and development | | | | | | | | |
| Equity in earnings | | | | | | | | |
| Other operating expenses | 833.1 | 643.5 | 535.1 | 465.7 | 414.6 | | 344.3 | 322.3 |
| EBITDA [+] | -393.4 | -12.3 | -156.7 | 380.3 | -48.8 | 39.4 | -11.1 | -67.4 |
| EBITDA growth | 3086.6% | -92.1% | -141.2% | -878.7% | -224.0% | -454.1% | -83.5% | 67.6% |
| EBITDA margin | -67.0% | -1.5% | -21.5% | 33.9% | -8.1% | 7.7% | -3.0% | -23.8% |
| Depreciation | 14.3 | 15.5 | 13.4 | 12.5 | 10.7 | 6.7 | 7.5 | 7.0 |
| EBITA | -407.8 | -27.8 | -170.0 | 367.8 | -59.6 | 32.7 | -18.6 | -74.4 |
| EBITA margin | -69.4% | -3.4% | -23.3% | 32.8% | -9.9% | 6.4% | -5.0% | -26.2% |
| Amortization of intangibles | 2.4 | 2.4 | 2.1 | 1.9 | 1.8 | 1.6 | 1.6 | 1.4 |
| EBIT [+] | -410.2 | -30.2 | -172.1 | 365.9 | -61.4 | 31.0 | -20.2 | -75.8 |
| EBIT growth | 1258.9% | -82.5% | -147.0% | -696.2% | -297.7% | -254.0% | -73.4% | 58.7% |
| EBIT margin | -69.8% | -3.7% | -23.6% | 32.6% | -10.2% | 6.0% | -5.4% | -26.7% |
| Interest expense, net [+] | -17.2 | -0.7 | -21.1 | -39.6 | 14.4 | 36.6 | 33.3 | 32.4 |
| Interest expense | 8.1 | 9.3 | 9.5 | 12.4 | 44.8 | 44.8 | 38.8 | 36.7 |
| Interest income | 25.3 | 10.0 | 30.6 | 52.0 | 30.4 | 8.2 | 5.5 | 4.4 |
| Other income (expense), net [+] | 135.0 | 0.3 | 16.5 | -66.7 | -0.4 | -11.2 | -4.0 | 20.2 |
| Gain (loss) on investments | -7.3 | 10.1 | 16.5 | 0.2 | -0.2 | | | |
| Gain (loss) on debt retirement | | | | -66.2 | | | -4.0 | |
| Other | -7.3 | -9.8 | -0.1 | -0.7 | -0.2 | -3.5 | | |
| Pre-tax income | -258.0 | -29.1 | -134.6 | 338.8 | -76.2 | -16.8 | -57.5 | -87.9 |
| Income taxes | 11.7 | -0.6 | 345.2 | 51.5 | -291.1 | -6.0 | 2.9 | 0.4 |
| Tax rate | | 1.9% | | 15.2% | 382.3% | 35.7% | | |
| Minority interest | | | -35.5 | 9.1 | -58.8 | -11.1 | | |
| Net income | -269.7 | -28.6 | -444.3 | 278.1 | 273.7 | 0.3 | -60.4 | -88.3 |
| Net margin | -45.9% | -3.5% | -60.9% | 24.8% | 45.6% | 0.1% | -16.2% | -31.1% |
| |
| Basic EPS [+] | ($1.90) | ($0.20) | ($3.18) | $1.99 | $2.07 | $0.00 | ($0.50) | ($0.74) |
| Growth | 837.7% | -93.6% | -260.2% | -4.0% | 74050.8% | -100.6% | -32.3% | 122.6% |
| Diluted EPS [+] | ($1.90) | ($0.20) | ($3.18) | $1.82 | $2.04 | $0.00 | ($0.50) | ($0.74) |
| Growth | 837.7% | -93.6% | -275.2% | -11.1% | 74319.3% | -100.5% | -32.3% | 122.6% |
| |
| Shares outstanding (basic) [+] | 141.8 | 141.0 | 139.6 | 140.0 | 132.3 | 124.0 | 120.9 | 119.7 |
| Growth | 0.6% | 1.0% | -0.3% | 5.8% | 6.7% | 2.5% | 1.0% | 1.7% |
| Shares outstanding (diluted) [+] | 141.8 | 141.0 | 139.6 | 153.2 | 134.1 | 126.1 | 120.9 | 119.7 |
| Growth | 0.6% | 1.0% | -8.8% | 14.3% | 6.3% | 4.3% | 1.0% | 1.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|